Literature DB >> 22996148

Gender-specific alterations in fibrin structure function in type 2 diabetes: associations with cardiometabolic and vascular markers.

Saad H Alzahrani1, Katharina Hess, Jackie F Price, Mark Strachan, Paul D Baxter, Richard Cubbon, Fladia Phoenix, T Gamlen, R A S Ariëns, Peter J Grant, Ramzi A Ajjan.   

Abstract

CONTEXT: Diabetes is associated with increased incidence of atherothrombotic disease. The fibrin network forms the backbone of the arterial thrombus, and fibrin clot structure determines predisposition to cardiovascular events.
OBJECTIVES: The aim of the study was to investigate fibrin clot structure/fibrinolysis in the largest type 2 diabetes cohort and analyze associations with cardiometabolic risk factors and vascular pathology.
DESIGN: Clot structure/fibrinolysis was assessed in 875 participants of the Edinburgh Type 2 Diabetes Study [age, 68 (range, 60-75) yr; 450 males] by turbidimetric assays, and clots were visualized by confocal microscopy. Four parameters of clot structure/fibrinolysis were analyzed, and plasma levels of fibrinogen and plasminogen activator inhibitor-1 were studied by Clauss assay and ELISA, respectively.
RESULTS: Clot maximum absorbance was increased in females compared with males (0.37 ± 0.005 and 0.34 ± 0.005 arbitrary unit, respectively; P < 0.001), and took longer to lyse (803 ± 20 and 665 ± 12 sec, respectively; P < 0.001). These gender differences in clot structure and fibrinolysis were still evident after correcting for fibrinogen and plasminogen activator inhibitor-1 plasma levels. A prothrombotic fibrin structure profile was associated with increased body mass index and low levels of high-density lipoprotein in women and with inadequate diabetes control in men. Clot formation time was related to previous cardiac ischemic events in both men and women after adjusting for traditional risk factors [odds ratio, 1.22 (95% confidence interval, 1.07, 1.38); and 1.33 (1.15, 1.50), respectively], and prothrombotic clots were associated with low ankle brachial index, renal impairment, and smoking, regardless of gender.
CONCLUSIONS: Women with type 2 diabetes have compact clots with compromised fibrinolysis compared with men. There are gender-specific associations between clotting parameters and cardiometabolic risk factors in this population, whereas vascular abnormalities, impaired renal function, and smoking are associated with prothrombotic clot structure profile regardless of gender.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22996148     DOI: 10.1210/jc.2012-2128

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  21 in total

1.  Insulin resistance and cardiovascular risk marker evaluation in morbid obesity 12 months after bariatric surgery compared to weight-matched controls.

Authors:  Alison J Dawson; Thozhukat Sathyapalan; Peter Sedman; Ramzi Ajjan; Eric S Kilpatrick; Stephen L Atkin
Journal:  Obes Surg       Date:  2014-03       Impact factor: 4.129

Review 2.  The Diabetes-Cardiovascular Connection in Women: Understanding the Known Risks, Outcomes, and Implications for Care.

Authors:  Eric K Broni; Chiadi E Ndumele; Justin B Echouffo-Tcheugui; Rita R Kalyani; Wendy L Bennett; Erin D Michos
Journal:  Curr Diab Rep       Date:  2022-02-14       Impact factor: 4.810

3.  The impact of gender and peripheral blood parameters on the characteristics of L-PRF membranes.

Authors:  Catherine Andrade Aldana; Felipe Ugarte Amenabar; Carolina Inostroza Silva; Paulo Diaz Calderon; David Rosenberg Messina; Nelson Pinto Carrasco; Marc Quirynen
Journal:  J Oral Biol Craniofac Res       Date:  2022-09-01

Review 4.  Mechanisms of cardiovascular complications in chronic kidney disease: research focus of the Transregional Research Consortium SFB TRR219 of the University Hospital Aachen (RWTH) and the Saarland University.

Authors:  Nikolaus Marx; Heidi Noels; Joachim Jankowski; Jürgen Floege; Danilo Fliser; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2018-05-04       Impact factor: 5.460

5.  Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications.

Authors:  Katherine J Kearney; Nikoletta Pechlivani; Rhodri King; Christian Tiede; Fladia Phoenix; Ramsah Cheah; Fraser L Macrae; Katie J Simmons; Iain W Manfield; Kerrie A Smith; Benjamin E J Spurgeon; Khalid M Naseem; Robert A S Ariens; Michael J McPherson; Darren C Tomlinson; Ramzi A Ajjan
Journal:  Blood       Date:  2018-12-13       Impact factor: 22.113

6.  The effects of treatment with liraglutide on atherothrombotic risk in obese young women with polycystic ovary syndrome and controls.

Authors:  Hassan Kahal; Ahmed Aburima; Tamas Ungvari; Alan S Rigby; Anne M Coady; Rebecca V Vince; Ramzi A Ajjan; Eric S Kilpatrick; Khalid M Naseem; Stephen L Atkin
Journal:  BMC Endocr Disord       Date:  2015-04-02       Impact factor: 2.763

7.  Gender discrimination for women with diabetes mellitus in Algeria.

Authors:  Farida Chentli; Said Azzoug; Djamila Meskine; Aldjia El Gradechi
Journal:  Indian J Endocrinol Metab       Date:  2014-11

8.  Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3.

Authors:  Katharina Hess; Saad H Alzahrani; Jackie F Price; Mark W Strachan; Natalie Oxley; Rhodri King; Tobias Gamlen; Verena Schroeder; Paul D Baxter; Ramzi A Ajjan
Journal:  Diabetologia       Date:  2014-05-17       Impact factor: 10.122

9.  BCL11A gene DNA methylation contributes to the risk of type 2 diabetes in males.

Authors:  Linlin Tang; Lingyan Wang; Huadan Ye; Xuting Xu; Qingxiao Hong; Hongwei Wang; Leiting Xu; Shizhong Bu; Lina Zhang; Jia Cheng; Panpan Liu; Meng Ye; Yifeng Mai; Shiwei Duan
Journal:  Exp Ther Med       Date:  2014-06-12       Impact factor: 2.447

10.  Lp(a) is not associated with diabetes but affects fibrinolysis and clot structure ex vivo.

Authors:  Marianne Månsson; Inge Kalies; Göran Bergström; Caroline Schmidt; Anne Legnehed; Lillemor Mattsson Hultén; Lena Amrot-Fors; David Gustafsson; Wolfgang Knecht
Journal:  Sci Rep       Date:  2014-06-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.